Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy—A prospective case series
- 24 October 2005
- journal article
- clinical trial
- Published by Wiley in American Journal of Hematology
- Vol. 80 (3), 197-203
- https://doi.org/10.1002/ajh.20471
Abstract
Administration of immunosuppressive treatment in hepatitis B virus carriers with malignancies is associated with the risk of hepatitis B reactivation. This complication is more frequent in patients with hematologic malignancies because administration of corticosteroids, the mainstay of treatment of these patients, is an independent risk factor for hepatitis B reactivation. When lamivudine is given prior to chemotherapy, it prevents the viral replication during the immunosuppression period; therefore, it might reduce the risk of hepatitis B exacerbation. We performed a prospective study to assess the efficacy of prophylactic administration of lamivudine in this setting. Ten hepatitis B virus carriers with hematologic malignancies were included in this study; seven were HBsAg positive, and three had isolated antiHBc and detectable HBV‐DNA levels. Nine patients were given corticosteroids after the administration of lamivudine. Lamivudine was given per os at a dose of 100 mg once daily. In four patients that had not been previously treated with chemotherapy, lamivudine was started 19 days (median) (range, 0–35 days) prior to the onset of chemotherapy. The administration of lamivudine has not stopped since in any of our patients. After a median follow‐up of 15 months (range 6–38 months), no hepatitis B reactivation was observed. HBV‐DNA levels were decreased in all 6 patients who had detectable HBV‐DNA at baseline. Lamivudine was well tolerated. Chemotherapy regimens were administered as planned, and their effectiveness was not compromised by lamivudine. In conclusion, prophylactic administration of lamivudine should be considered as a means of reducing the frequency of hepatitis B reactivation in hepatitis B virus carriers with hematologic malignancies who are being treated with chemotherapy. Am. J. Hematol. 80:197–203, 2005.Keywords
This publication has 43 references indexed in Scilit:
- Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximabAmerican Journal of Hematology, 2001
- A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphomaBone Marrow Transplantation, 2001
- Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivationBritish Journal of Haematology, 2000
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Identification and characterization of mutations in hepatitis B virus resistant to lamivudineHepatology, 1998
- Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapyEuropean Journal of Cancer, 1992
- Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatmentDigestive Diseases and Sciences, 1992
- Spontaneous Reactivation in Chronic Hepatitis BJournal of Clinical Gastroenterology, 1990
- CHANGING OF HEPATITIS B VIRUS MARKERS IN PATIENTS WITH BONE MARROW TRANSPLANTATIONTransplantation, 1990
- Recurrence of hepatitis B in children with serologic evidence of past hepatitis B virus infection undergoing antileukemic chemotherapyJournal of Hepatology, 1989